You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 144 No. 10, October 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatology
 •Dermatologic Disorders
 •Dermatologic Disorders, Other
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Type I Interferon in the Induction or Exacerbation of Dermatomyositis

What This Observation Tells Us About the Naturally Occurring Disease

David F. Fiorentino, MD, PhD

Arch Dermatol. 2008;144(10):1379-1382.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Adverse events associated with medication use are a bane for physicians. However, when an adverse effect goes beyond an isolated clinical or laboratory finding and is instead a phenocopy of a naturally occurring disease state, we are presented with an opportunity to understand disease pathogenesis. The less common situation in which a disease state is reproduced with a naturally occurring biologic substance (ie, cytokine or hormone) makes even the most jaded of clinicians stand up and take note. The association of supraphysiologic amounts of an endogenous molecule with an induced disease state hardly provides physiologic proof of its connection in the spontaneously occurring disease, but it provides another level of evidence in a world in which the study of human disease rarely affords one with the opportunity to perform an in vivo experiment. It is with this level of interest and caution that we should . . . [Full Text of this Article]


AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Severe Dermatomyositis Triggered by Interferon Beta-1a Therapy and Associated With Enhanced Type I Interferon Signaling
Ally-Khan Somani, Alan R. Swick, Kevin D. Cooper, and Thomas S. McCormick
Arch Dermatol. 2008;144(10):1341-1349.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.